GLP-1R market: A two-horse race, says GlobalData As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion by 2030 The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their ability to effectively treat metabolic-related disorders such as obesity and type 2 diabetes
Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats
Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
Lumen: Metabolic Insights Lumen isn't GLP-1 specific, but it provides valuable metabolic feedback
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J
A.HawkinsR.GreenspanF